Juan Andres - Moderna Chief Technical Operations and Quality Officer

0QF Stock  EUR 39.78  2.92  6.84%   

Insider

Juan Andres is Chief Technical Operations and Quality Officer of Moderna since 2018.
Age 58
Tenure 6 years
Phone617 714 6500
Webhttps://www.modernatx.com

Moderna Management Efficiency

The company has return on total asset (ROA) of 0.233 % which means that it generated a profit of $0.233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.5027 %, meaning that it generated $0.5027 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.
Moderna has accumulated 603 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 1.22, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jill HoytNovavax
N/A
Richard CrowleyNovavax
66
Jens HolsteinBioNTech SE
60
Filip DubovskyNovavax
N/A
John IIINovavax
57
James YoungNovavax
66
Richard DouglasNovavax
66
MBA BSNovavax
63
John HerrmannNovavax
53
Frank CzworkaNovavax
46
Ozlem MDBioNTech SE
56
Rajiv ModiNovavax
58
Michael McManusNovavax
76
James RyanBioNTech SE
N/A
James CFANovavax
57
Gregory GlennNovavax
69
Brian WebbNovavax
N/A
Sean MarettBioNTech SE
58
David MottNovavax
53
Gary EvansNovavax
61
Sierk PoettingBioNTech SE
50
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people. Moderna (0QF) is traded on Frankfurt Exchange in Germany and employs 3,900 people.

Management Performance

Moderna Leadership Team

Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marcello Damiani, Chief Digital and Operational Excellence Officer
Shannon Klinger, Chief Sec
James Mock, Chief Officer
Stephane Bancel, Chief Executive Officer, Director
Lori Henderson, General Counsel, Company Secretary
Tal Zaks, Chief Medical Officer
John Reynders, Chief Officer
Paul Sagan, Non-Executive Independent Director
Lavina CFA, VP Relations
Melissa Moore, Chief Board
Francois Nader, Non-Executive Independent Director
Elizabeth Tallett, Director
Stephen Hoge, President
Noubar Afeyan, Non-Executive Independent Chairman of the Board, Co-Founder
Stephen Berenson, Non-Executive Independent Director
Stephen MD, President
Robert Langer, Non-Executive Independent Director
Tracey Franklin, Chief Human Resource Officer
Ray Jordan, Chief Corporate Affairs Officer
Jerh Collins, Chief Officer
Juan Andres, Chief Technical Operations and Quality Officer
Israel Ruiz, Non-Executive Independent Director
David Meline, Chief Financial Officer

Moderna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Moderna Stock

When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Moderna Stock please use our How to Invest in Moderna guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.